Catalog makes Hartwig Medical Database easily searchable
Hartwig Medical Foundation maintains a catalog of the Hartwig Medical Database with whole-genome data on full tumor genomes: https://catalog.hartwigmedicalfoundation.nl. The database currently contains data on over 5,800 patients, including treatment and response data. In addition, this database contains RNA sequencing data from more than half of the patients.
Hartwig Medical Foundation’s mission is to provide the best possible care for today’s patient as well as the patient of tomorrow. An important part of this is making genomic and relevant clinical data available to research groups, with consent from the patients involved. The public catalog of Hartwig Medical Database makes it easy to gain insight into the available data, enabeling a quick and easy overview if there are tumor genomes in the database of interest to the researcher.
The catalog is interactive and the database can be viewed through flexible visualizations of different data types in multiple dimensions. Filtering is possible per data type, e.g. tumor type, biopsy location, age, gender, treatment given, treatment outcome and RNA availability.
This is the world’s largest publicly available dataset of its kind. It is available free of charge for research to improve the care for cancer patients of today and tomorrow. Hartwig Medical Foundation is grateful for the cooperation of so many patients, they have chosen to share their data for the benefit of science and other patients.
For the conditions and procedures for requesting access to the data, please visit our website.
Hartwig Medical Foundation collects data in collaboration with the CPCT, the Netherlands Cancer Institute and more than 40 Dutch hospitals with the consent of patients in various studies.
This unique source is continuously growing with increasing adaptation of complete genome diagnostics in regular healthcare in the Netherlands. Cancer of unknown primary origin is the first indication with a reimbursement title for this test and shows clearly the added value for patients in daily practice.
All news
Also read
New research shows a more significant role of genetic predisposition in adults with glioblastoma
A recent study published in npj Genomic Medicine shows that hereditary predisposition in adult glioblastoma patients is more common than …
Hartwig receives CE certification for OncoAct, the first complete IVDR-certified whole-genome cancer diagnostics solution
We are proud to announce that Hartwig Medical Foundation has received CE certification under the European In Vitro Diagnostic Regulation …
Metastatic bladder cancer: new insights into tumour spread and chemotherapy resistance
Hartwig data supports new Nature study on lethal metastatic bladder cancer. Researchers used the Hartwig Medical Database to independently validate …
The fact that the CPCT, together with Hartwig Medical Foundation, has managed to bundle data, knowledge and expertise from almost all Dutch hospitals is unique and now also deserves international attention.